Chadi Nabhan, MD, MBA, FACP
Chadhi Nabhan, MD, MBA, FACP, is a hematologist/oncologist and award-winning host of the “Outspoken Oncology” and “Healthcare Unfiltered” podcasts.
Articles by Chadi Nabhan, MD, MBA, FACP
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD continue their discussion on MRD in CLL during HOP Live 2024.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Among the major dilemmas persisting in CAR-T therapy use is how to balance malignancy risks.
Dr. Shammo gives her impressions of how growing incorporation of MDS molecular data is changing disease management.
This episode explores questions in CLL with Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD during HOP Live 2024.
Dr. Pemmaraju discusses three major unanswered questions for myeloproliferative neoplasm researchers.
Amer Zeidan, MBBS, discusses the unanswered questions in research related to myelodysplastic syndromes.
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
Himachandana Atluri, MD, describes the experience and ins and outs of becoming a new fellow.
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
Michael Bishop MD; Aaron Goodman, MD; and Rafael Fonseca, MD, discuss bispecifics in hematologic malignancies.
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
The panel discussed treatment options for Hodgkin lymphoma, maintenance therapy following autologous transplant, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.